These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1615121)

  • 21. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
    Morelli M; Fenu S; Pinna A; Di Chiara G
    J Pharmacol Exp Ther; 1992 Jan; 260(1):402-8. PubMed ID: 1346165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early L-dopa treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation.
    Carey RJ; Pinheiro-Carrera M; Tomaz C; Huston JP
    Brain Res; 1994 Sep; 658(1-2):145-54. PubMed ID: 7834335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.
    Ponten H; Kullingsjö J; Sonesson C; Waters S; Waters N; Tedroff J
    Eur J Pharmacol; 2013 Jan; 698(1-3):278-85. PubMed ID: 23127496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Glavan G; Zivin M
    Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of neuroleptic haloperidol, L-DOPA precursor dopamine, and neurotoxic dopamine analog 6-OHDA on acquisition of conditioned defensive reflex in edible snail.
    Muranova LN; Andrianov VV; Gainutdinov KhL
    Bull Exp Biol Med; 2009 Nov; 148(5):750-3. PubMed ID: 20396784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
    Blunt S; Jenner P; Marsden CD
    Neuroscience; 1991; 40(2):453-64. PubMed ID: 1902916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-dopa stimulates the release of [3H]gamma-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats.
    Aceves J; Floran B; Martinez-Fong D; Sierra A; Hernandez S; Mariscal S
    Neurosci Lett; 1991 Jan; 121(1-2):223-6. PubMed ID: 1902287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uridine reduces rotation induced by L-dopa and methamphetamine in 6-OHDA-treated rats.
    Myers CS; Fisher H; Wagner GC
    Pharmacol Biochem Behav; 1995 Dec; 52(4):749-53. PubMed ID: 8587915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.
    Carey RJ
    Psychopharmacology (Berl); 1986; 89(3):269-72. PubMed ID: 3088649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S; Ramsay Croft N; Jenner P
    Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine potentiates L-DOPA-induced contralateral rotation in 6-hydroxydopamine-treated rats.
    Adams AC; Keefe KA
    Neurosci Lett; 1999 Oct; 274(1):25-8. PubMed ID: 10530511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reinstatement by caffeine of an extinguished conditioned dopaminergic drug response.
    Carey RJ
    Pharmacol Biochem Behav; 1990 May; 36(1):127-32. PubMed ID: 2349255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.